| Summary: | The objective of this report is to perform a systematic review of the beneficial and harmful effects of vedolizumab intravenous (IV) infusion in accordance with the Health Canada-approved indication for the treatment of Crohn's disease. Vedolizumab has been previously reviewed through the CADTH Common Drug Review (CDR) for the treatment of ulcerative colitis. Vedolizumab is available in single-use vials containing 300 mg of vedolizumab. It is administered via IV infusion and must be reconstituted and diluted prior to administration. For the treatment of Crohn's disease, the product monograph for vedolizumab recommends a dosage of 300 mg IV at initiation (i.e., week 0), two weeks, six weeks, and then every eight weeks thereafter. The product monograph states that therapy with vedolizumab should be discontinued for patients who fail to show evidence of therapeutic benefit by 14 weeks
|
|---|